Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 21, 2025
Rectify Pharma to Present Translational Data on Novel Approach to Treat Chronic Kidney Disease and Vascular Calcification at ERA 2025
GlobeNewswire
·
May 21, 2025
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, today announced that it will present a …
Konica Minolta Healthcare to Launch Integrated Teleradiology Solution Powered by NewVue
GlobeNewswire
·
May 21, 2025
TAMPA, Fla. and WAYNE, N.J., May 21, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., a pioneer in imaging and healthcare IT innovation, and NewVue, the leading provider of intelligent, cloud-native radiology workflow solutions, today …
Kaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101
GlobeNewswire
·
May 21, 2025
Represents significant milestone in the development of KAD101, a novel biologic prolactin receptor antagonist, being initially developed for the treatment of platinum resistant ovarian cancer (PROC) with expansion opportunities into endometrial, uterine …
Route 92 Medical Announces Results of SUMMIT MAX Clinical Trial Showing Highest First Pass Effect Ever Reported in a Randomized Endovascular Stroke Thrombectomy Study
GlobeNewswire
·
May 21, 2025
Data from 250-patient, 31-center, randomized controlled trial presented at European Stroke Organisation Conference Three highest enrolling sites reported 96% delivery of the super-bore HiPoint 88 Reperfusion System to MI occlusions and 84% first pass …
Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease
GlobeNewswire
·
May 21, 2025
Maintains Brain Connectivity: GAL-201 prevents amyloid-beta (Aβ)–induced synaptic damage by maintaining long-term potentiation, a correlate for learning and memory. Improves Memory and Behavior: Preclinical testing shows significant improvements in spatial …
The Beauty Health Company Announces Convertible Debt Refinancing
GlobeNewswire
·
May 21, 2025
LONG BEACH, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced that it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain …
Quipt Home Medical Confirms Receipt of Unsolicited Acquisition Proposal
GlobeNewswire
·
May 21, 2025
CINCINNATI, May 21, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider focused on end-to-end respiratory care, today announced that it has received an …
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees
GlobeNewswire
·
May 21, 2025
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors’ Recommendation and Vote “FOR” Wendy L. Dixon, Ph.D. and Tamara A. Favorito on the …
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
GlobeNewswire
·
May 21, 2025
The Company demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models Raanana, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company …
Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
GlobeNewswire
·
May 21, 2025
MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of …
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
GlobeNewswire
·
May 21, 2025
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that …
Rapport Therapeutics to Host 2025 Investor and Analyst Day
GlobeNewswire
·
May 21, 2025
BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or …
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
GlobeNewswire
·
May 21, 2025
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University of North Carolina (UNC) and supported by a grant …
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 21, 2025
MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including …
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 21, 2025
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company …
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
GlobeNewswire
·
May 21, 2025
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in …
GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting
GlobeNewswire
·
May 21, 2025
Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology. SAN MARINO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- GenVivo …
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 21, 2025
VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at …
NeurAxis Announces $5.0 Million Registered Direct Offering
GlobeNewswire
·
May 21, 2025
CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases
GlobeNewswire
·
May 21, 2025
Paris, France – May 21, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, today announces the evolution of its Scientific Advisory Board (SAB). This renewed SAB reflects Coave’s strategic shift from a platform- …